IP Library › Granted Patent US 45,992
Granted Patent E1
US 45,992 · App. 14/338,413 · Granted May 3, 2016

Optimized FC variants

Inventors: Christian Behrens (Palaiseau, FR); Sylvie Jorieux (Villeneuve D'Ascq, FR); Abdelhakim Kharrat (Montgiscard, FR); Khalil Bouayadi (Ramonville Saint Agne, FR); Philippe Mondon (Donneville, FR); Celine Monnet-Mars (Blagnac, FR)
Assignee: LABORATOIRE FRANCAIS DU FRACTIONNEMENT ET DES BIOTECHNOLOGIES
C07K16/00C07K2317/21C07K2317/52C07K2317/92
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 45,992
App. No.
14/338,413
Granted
May 3, 2016
Kind
E1
Abstract

A variant of a parent polypeptide including an Fc region, which variant exhibits increased binding to FcRn as compared to the parent polypeptide and includes at least one amino acid modification in the Fc region.

Claims (24)

1. A variant of a parent polypeptide comprising a Fc region, which variant exhibits increased binding to FcRn as compared to said parent polypeptide and comprises

a combination of amino acid modifications selected from the group consisting of:

N315D/A330V/N361D/A378V/N434Y,

V264E/N315D/A378V/N390S/G420R/N434Y,

N315D/A378V/N434Y,

N315D/A330V/A378V/N434Y,

N315D/K334E/A378V/N434Y,

V264E/N315D/A378V,

P228R/N315D/A330V/N361D/A378V/N434Y,

P228R/P230S/N315D/A330V/N361D/A378V/N434Y,

P228L/N315D/A330V/N361D/A378V/N434Y,

P228L/P230S/N315D/A330V/N361D/A378V/N434Y,

P230S/N315D/A330V/N361D/A378V/N434Y,

P230T/V264E/N315D/K370R/A378V,

of the Fc region, wherein the numbering of the amino acids in the Fc region is that of the EU index as in Kabat.

2. The variant according to claim 1 , wherein said variant is an antibody.

3. The variant according to claim 2 , wherein said antibody is an IgG antibody.

4. A pharmaceutical composition comprising a variant as defined in claim 1 .

5. A medicament comprising a variant according to claim 1 .

6. An isolated nucleic acid encoding a variant as defined in claim 1 .

7. A vector comprising the nucleic acid of claim 6 .

8. An isolated host cell containing the vector of claim 7 .

9. A method for producing a variant according to claim 1 , comprising culturing a host cell containing a vector comprising an isolated nucleic acid encoding said variant so that the nucleic acid is expressed.

10. A variant according to claim 1, wherein the Fc region of the parent polypeptide is SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, or SEQ ID NO: 4.

Assignments (2)
CHANGE OF OWNER/APPLICANT'S ADDRESS Recorded Apr 3, 2023
From: LABORATOIRE FRANÇAIS DU FRACTIONNEMENT ET DES BIOTECHNOLOGIES
To: LABORATOIRE FRANÇAIS DU FRACTIONNEMENT ET DES BIOTECHNOLOGIES
Reel/Frame 063237/0439 →
CHANGE OF OWNER/APPLICANT'S ADDRESS Recorded Sep 21, 2022
From: LABORATOIRE FRANÇAIS DU FRACTIONNEMENT ET DES BIOTECHNOLOGIES
To: LABORATOIRE FRANÇAIS DU FRACTIONNEMENT ET DES BIOTECHNOLOGIES
Reel/Frame 061493/0885 →
Priority Claims (1)
EP 09305250 · Mar 20, 2009 · regional
Continuity (1)
Reissue 13257502 · Mar 19, 2010